The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb.

Findings of the South African study in the Oxford AstraZeneca Covid-19 vaccine trial were published in the <i>New England Journal of Medicine</i> (<i>NEJM</i>), the leading medical journal globally, on Tuesday, 16 March 2021, following peer review.

A new study uncovers which cell types can be infected by SARS-CoV-2 due to their viral entry factors. The study also suggests that increased gene expression of these viral entry factors in some individuals partially explains the differences of COVID-19 severity reported in relation to age, gender and smoking status.